Composition for stimulation of energy metabolic processes and method of prevention of patrimonial pathologies and postnatal diseases of cows

FIELD: agriculture.

SUBSTANCE: group of inventions relates to the field of animal husbandry and is intended for stimulation of energy metabolic processes and to the method of prevention of patrimonial pathologies and postnatal diseases at cows. The offered composition for stimulation of energy metabolic processes includes the use of amber acid as an energy stimulator. A carbohydrate component is beet treacle, it is used in the following ratio of components per 1 litre: amber acid - 15 g, beet treacle - 500 g, water - the rest. The offered method includes the administration of the named composition a days before calving and during the first hours after calving.

EFFECT: use of the offered group of inventions allows to provide high power activity in organisms of animals during the predicted periods of risk of development of serious pathobiochemical processes, in particular in prenatal and postnatal periods.

2 cl, 2 tbl, 1 ex

 

The invention relates to livestock and can be used in veterinary medicine for the prevention and treatment of specific disease of cows caused by disorders of metabolism and energy failure.

Currently high rates of milk production of cows in the livestock industry are achieved mainly by the use in the rations of concentrated feed. With a lack of carbohydrates in the diet, this type of feeding leads to rapid development pathobiochemical processes, manifested by acidosis and ketosis. Because of the shortage of carbohydrates in the rumen of cows there will be insufficient amounts of acetic and propionic acids, resulting in the synthesis of glucose in the liver is reduced, which leads to a decrease in its concentration in blood and the development of the energy crisis. The lack of energy in the body is the cause of hard labor, detention of the placenta after calving and, as a consequence, diseases endometritis. Recover from endometritis animals often become infertile.

Development acidsnow and cloznogo process causes a marked reduction of functional activity of the liver and the weakening of protective forces of an organism. This background is favorable for the activation of endogenous pathogens infections.

In this regard, the issues of ensuring ZD�revia cows in the prenatal and postnatal periods are relevant to modern dairy farming.

To reduce the risk of development pathobiochemical processes in cows in the livestock industry has developed and applied a huge Arsenal of feed additives. In particular,developed a whole series of drugs "Flucan". Drugs series "Flucan" is quite well established in dairy cattle. They are designed for constant use of them in the diet of the cows. This can significantly reduce the problem of feeding the cows. Nevertheless, the high incidence of cows with steatosis indicate that they are not effective as hepatoprotectors.

There is a significant amount of imported additives with metabolic and energetic activity (such as "Lacto-energy", "Selco-energy", etc.).

Known drug "Privaten" (Patent RF №2289832 from 10.09.2005). The composition of the drug Privaten includes the following components: weight. %: riboxinum 10,0-40,0; calcium glycerophosphate 30,0-40,0; vitamin B12 0,02-0,04; ascorbic acid 2-4; citric acid 2; succinic acid 2-4; folic acid 1-2, fructose 5-10, glucose and 100.

The inclusion of the drug in animal feeding and the birds proved to be very effective. The drug are improves metabolism, increases resistance to infectious diseases. However, the drug contains in its composition components, in particular glucose, fructose, Kotor�e are considered to be quite scarce, which significantly restricts its production.

The closest part of the energy tools, selected as a prototype is a biologically active additive "Antavit".

Antavit - this tablet form, containing one tablet (0.5 g), 0.4 g of glucose and 0.1 g of succinic acid. The use of anavita shown to stimulate energy metabolism, toxicosis of different Genesis, in the period of severe debilitating diseases. However, this pharmaceutical composition is intended for people and cannot be considered sufficiently convenient form for application to animals. In addition, glucose is an expensive component that makes it unprofitable for application to animals.

The object of the invention is to obtain an effective drug that provides high energy activity in animals in predictable periods of risk of developing severe pathobiochemical processes, particularly in the prenatal and postnatal periods.

To solve this problem is proposed the integrated energodialoga of the drug on the basis of beet molasses or sugar syrup and succinic acid.

Beet molasses is widely used in the livestock industry as a source of carbohydrates, improve the taste of feed. Its inclusion in the diet of lactating cows significantly povyshe� fat milk. In veterinary practice it has long been used to activate uterine contractions during childbirth and the expulsion of afterbirth (I. E. Brain Pharmacology. Kolos, 1974. - 169 p.).

Succinic acid and its salts have a broad spectrum of effects on various mechanisms of regulation of metabolic activity of cells. The object of the action of succinic acid are cells and tissues that are in a state of excitement or pathologically altered. Absolute harmlessness of succinic acid and its compounds with the ability to have a positive effect in low dosages, making it very attractive when developing a new generation of so-called "smart" drugs (Kondrashova M. N., 1996).

Succinic acid is a potent stimulator of energy production in the cells, which is especially important when different kinds of pathophysiological conditions, when the body does not have enough energy for normal vital functions;

- succinic acid tenfold increases cellular respiration, which improves the absorption of oxygen by cells, tissues, organs and, on the contrary, neutralizes aggressive forms of oxygen;

- succinic acid normalizes the nervous system, which is important in the response to stress;

- succinic acid inhibits inflammation and neutralizes the toxins that have� important in Toxicological diseases.

Stimulating effect of succinic acid is particularly pronounced in the weakening of the body and its diseases.

High energy and metabolic activity of the composition is related to the integrated action of its main components.

A method of obtaining a composition is to dissolve in tap water by heating succinic acid, sodium chloride, mixed with beet molasses or sugar syrup.

Composition for stimulation energomehanicheskih processes, including as an energy stimulant use of succinic acid and beet molasses, and, as a carbohydrate component beet molasses is used in the following ratio of components per 1 liter:

Succinic acid 15 g

Beet molasses - 500 grams

Water - the rest.

In our own experiments revealed that a single oral application of succinic acid in the amount of 15-25 grams on cows with an average body weight of 550-600 kg ensures elimination of nutritional acidosis, which indicates the normalization of the fundamental metabolic processes.

The use of succinic acid in an amount of less than 15 g per 1 head reduces the effect of eliminating nutritional acidosis with 80-70% to 30-20%.

Packaging of the composition is carried out in conventional plastic bottles with a volume less than 1 litre.

Low pH of 3.0 and 3.2, n is�favorable for the activity of the microflora, that allows you to keep the composition at room temperature for at least 6 months.

The method of application of the composition lies in the dilution of the contents of the bottle in 5-7 litres of tap water and feeding the cow the day before delivery or simple individual adding to food. It is advisable to repeat the country's energy structure and in the first hours after calving.

The efficacy of the tested composition was carried out on highly productive cows in two dairy complexes Kursk oblast the training farm "Znamenskoye" and JSC "Druzhba".

The average annual productivity of both herds is from 5500 to 6000 kg milk per cow.

Cows of the experimental group applied the test composition per day prior to calving and in the first hours after calving. In the period of the experiments take into account the birth weight, the frequency of the detention of the placenta, the incidence of acute postpartum endometritis. From 5 cows 4 years of age of each group was performed blood sampling for the study on the basic biochemical parameters (total protein, reserve alkalinity, glucose, calcium, inorganic phosphorus).

The results of clinical observations for birth weight are presented in table 1.

The results of biochemical studies of blood serum are presented in table 2.

After analyzing the data, it follows that the test stimulator of�AZAL pronounced effect on biochemical processes. So, in cows of the experimental group on day 7 after calving, the concentrations of protein and reserve alkalinity were within physiological values. In fact, the normalization of the indicator acid-base balance (reserve alkalinity) testified about the positive impact of the test stimulator for all biochemical processes in the organism of cows, including mineral metabolism. On the improvement of mineral metabolism can be judged by higher levels of serum calcium. On the contrary, in cows of the control groups reserve alkalinity did not change significantly relative to background values. This is evidence of decreased functional activity of the liver and the development acidsnow state.

Thus, based on the results of our experiments found that the combination of succinic acid with molasses or sugar syrup provides a high level of energy body stimulation cows in childbirth, and prevents the retention of the placenta, normalizes metabolism, caused by preeclampsia (toxemia).

Applying energy to the composition, on the above procedure, provides favorable for the generic process, timely separation of the placenta (table 1), expressed correction of metabolism, in private�ti eliminates the nutritional status of acidosis (table 2).

The combination of power means is characterized by ease of manufacture, availability of components and high efficiency prevention of the most common pathologies in cows associated with hyperemesis gravidarum and the energy crisis in childbirth. The novelty of the energetic composition is confirmed by the absence of such drugs among the currently used power tools in veterinary medicine.

The results of applying energy to the composition attest to its high efficiency to ensure the health and productivity of dairy cows complexes.

Table 2
The influence of the energy of the composition for hematological and biochemical processes of cows on the seventh day after calving (Uch households "Znamenskoye")
IndicatorsThe subject compositionControl
Total protein, g/l79,8+9,6181,4+8,55
87,8+9,5284,5+10,8
Reserve alkalinity, Yield 18.76+1,4518,92+1,34
General. CO2, mmol/l22,58+1,7414,76+1,42
Ketone bodies, mmol/l1,04+0,021,06+0,03
0,78+0,021,39+0,04
Calcium, mmol/l2,24+0,122,26+0,09
2,56+0,142,05+0,07
Phosphorus1,84+0,121,78+0,11
inorganic, mmol/l1,82+0,141,85+0,09
Glucose, mmol/l1,36+0,041,34+0,08
1,49+0,061,37+0,04

1. Composition for stimulation energomehanicheskih processes, including as an energy stimulant use of succinic acid and beet molasses, characterized in that the carbohydrate�component of beet molasses is used in the following ratio of components per 1 liter:
Succinic acid - 15g
Beet molasses - 500 g
Water - the rest

2. The way to prevent birth abnormalities and postpartum diseases in cows, comprising applying the composition according to claim 1 for the day before the birth and in the first hours after calving.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and represents clinical nutrition for prevention, treatment or relief of one or several symptoms, associated with impairment of metabolism or its disorder, which contains composition of polysaccharide high-viscosity dietary fibre, including viscous fibre mixture or its complex, consisting of from 48% to 90% in wt % of glucomannan, from 5 to 20 % in wt % of xanthan gum and from 5% to 30% in wt % of alginate, as well as, at least, one macroelement, selected from the group, consisting of protein carbohydrate and fat, where clinical nutrition is composed in order to provide dose of composition of polysaccharide high-viscosity dietary fibre from 20 g/day to 35 g/day for time period, effective for prevention, treatment and relief of one or several symptoms, associated with impairment of metabolism or its disorder.

EFFECT: invention ensures extension of arsenal of means, preventing, relieving or treating one or several symptoms, associated with impairment of metabolism or metabolic disease.

14 cl, 6 ex, 20 tbl, 48 dwg

FIELD: medicine.

SUBSTANCE: group of inventions relate to field of pharmaceutics, in particular, to pharmaceutical composition for treatment of phenylketonuria, which contains effective quantity of version of Anabaena variabilis (AvPAL) phenylalanine-ammonia-lyase, where claimed version additionally contains polyethylenglycol, as well as pharmaceutically acceptable carrier, which contains stabiliser, where stabiliser represents L-phenylalanine, trans-cinnamic acid or benzoic acid. Also claimed are: method of phenylketonuria treatment and method of reducing phenylalanine concentration in subject's blood.

EFFECT: group of inventions ensure application of prokaryotic PAL, which has higher phenylalanine-converting activity and/or lower immunogenicity in comparison with PAL of wild type.

56 cl, 19 ex, 11 tbl, 19 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to the field of biotechnology, namely to obtaining GLP-2 analogues, and can be used in medicine for treating GLP-2-associated disorders. The analogues of GLP-2 with agonistic activity with respect to GLP-2 receptors have been obtained.

EFFECT: invention makes it possible to increase resistance to proteases, which provides the lower clearance of the obtained analogues and prolongation of their bioavailability in comparison with native GLP-2.

29 cl, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and deals with application of aqueous balanced solution of electrolytes as external washing solution, for washing and purification in case of surgery, for washing and purification of wounds and burns, for washing body cavities, for eye washing, for washing and purification of instruments and in servicing stomas or as carrier solution for compatible electrolytes, nutrients and medications. Aqueous balanced solution contains: 138-146 mmol/l of sodium, 4-5 mmol/l of potassium, 0.5-2.0 mmol/l calcium, 1.0-1.5 mmol/l of magnesium, 100-108 mmol/l of chloride, 0.5-1.5 mmol/l of phosphate, 18-26 mmol/l of gluconate, 20-28 mmol/l of acetate.

EFFECT: invention makes it possible to use aqueous balanced solution as effective means of external washing solution or as carrier solution for compatible electrolytes, nutrients and medications.

11 cl, 2 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the field of organic chemistry, namely to derivatives of diaza-spiro[4.5]decan-1-one of formula (I) or to their pharmaceutically acceptable salts, where. R1 is a substituted phenyl, which contains one substituent, selected from the group, including C1-4-alkyl, C3-6-cycloalkyl halo-C1-4-alkyl and halo -C1-4-alkoxy, and which can additionally contain one substituent, selected from a halogen; R2 is hydrogen, C1-4-alkyl, phenyl, substituted phenyl, with the substituted phenyl containing one substituent, selected from the group, including C1-4-alkoxy; R3 is -R4, -C(OH)R5R6 or -C(O)NR7R8; R4 is phenyl, phenyl-C1-4-alkyl, substituted phenyl, substituted phenylcarbonyl, with the substituted phenyl, substituted phenylcarbonyl containing from one to two substituents, selected from the group, including a halogen, halo-C1-4-alkyl; one of R5 and R6 is hydrogen, C1-4-alkyl, and the other is aminocarbonyl, phenyl, substituted phenyl or substituted phenyl-C1-4-alkyl, with the substituted phenyl or substituted phenyl-C1-4-alkyl containing from one to two substituents, independently selected from the group, including a halogen; one of R7 and R8 is hydrogen C1-4-alkyl, and the other is C1-4-alkyl, C3-6-cycloalkyl, C1-4-alkoxy-C1-4-alkyl, phenyl-C1-4-alkyl, substituted phenyl or substituted phenyl-C1-4-alkyl, with the substituted phenyl or substituted phenyl-C1-4-alkyl containing one substituent, selected from the group, including a halogen, halo-C1-4-alkyl; or R7 and R8 together with a nitrogen atom, which they are bound to, form pyrrolidinyl; n equals zero or 1/ The invention also relates to a pharmaceutical composition based on the compound of formula (I), application of the formula (I) compound and a method of treatment.

EFFECT: obtained are novel heterocyclic compounds, useful as an inhibitor of hormone-sensitive lipase.

17 cl, 57 ex

FIELD: veterinary medicine.

SUBSTANCE: product comprises Lycopodium clavatum, Acidum arsenicosum, Phosphorus, Podophyllum peltatum, Thuja occidentalis, Echinacea purpurea, Silybum marianum, Selenocysteine, and the components are taken in the dilutions described below in the following ratio, in parts: Lycopodium clavatum ⌀=D1 0.004, Podophyllum peltatum ⌀ 0.003, Acidum arsenicosum ⌀=D2 0.0001, Phosphorus ⌀=D3 0.001, Thuja occidentalis ⌀ 30, Echinacea purpurea ⌀ 30, Silybum marianum ⌀ 60, Selenocysteine 0.2.

EFFECT: product has an effective stress-protective and growth-stimulating effect, it regulates the metabolism in young farm animals.

3 cl, 10 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of organic chemistry, namely to novel derivatives of pyrazole pyridine of formula , as well as to its tautomers, geometrical isomers, enantiomers, diastereomers, racemates and pharmaceutically acceptable salts, where G1 represents H; G2 represents -CHR1R2; R1 and R2 independently on each other are selected from H; C1C6-alkoxy-C1C6-alkyl; C1-C6-alkyl; optionally substituted phenyl; optionally substituted phenyl-C1-C6-alkyl; optionally substituted morpholine-C1-C6-alkyl; or -CHR1R2 together form a ring, selected from an optionally substituted C3-C8-cycloalkyl and substituted piperidine; G3 is selected from an optionally substituted C1C6-alkoxy -C1-C6-alkyl; C1-C6-alkyl; substituted phenyl; substituted phenyl-C1C6-alkyl; G4 is selected from a substituted acyl-C1C6-alkyl, where acyl represents a group -CO-R and R stands for H or morpholine; optionally substituted C1-C6-alkyl; optionally substituted phenyl or indene; substituted phenyl-C1-C6-alkyl; optionally substituted pyridine- or furanyl-C1C6-alkyl; morpholine- or piperidine-C1-C6-alkyl; G5 represents H; where the term "substituted" stands for the groups, substituted with 1 to 5 substituents, selected from the group, which includes a "C1-C6-alkyl," "morpholine", "C1-C6-alkylphenyl", "di-C1-C6-alkylamino", "acylamino", which stands for the group NRCOR", where R represents H and R" represents a C1-C6-alkyl, "phenyl", "fluorine-substituted phenyl", "C1-C6-alkoxy", "C1-C6-alkoxycarbonyl", "halogen". The invention also relates to a pharmaceutical composition based on the formula (I) compound and particular compounds.

EFFECT: obtained are the novel derivatives of pyrasole pyridine, useful for the treatment and/or prevention of disorders or states, associated with NADPH-oxidase.

12 cl, 3 tbl, 21 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to biotechnology. What is presented is the strain Bifidobacterium longum NCIMB 41676 possessing the immunomodulatory action. The above strain is applicable as an anti-infectious probiotic strain. What is also presented is a probiotic formulation containing the above strain and a carrier for oral administration. What is also presented is using the formulation as a cognitive function enhancer for preventing the central nervous system disorders, such as Alzheimer disease, schizophrenia and/or mild cognitive disorders. Alternatively, what is used is the formulation for preventing an inflammation related to obesity, for preventing metabolic disorders related to obesity.

EFFECT: group of inventions provides increasing anti-inflammatory cytokine IL-10 and decreasing proinflammatory cytokines and lipopolysaccharide induced HfkB activity.

37 cl, 16 dwg, 6 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: treating secondary mitochondrial dysfunction in the children suffering an urinogenital pathology is ensured by measuring a pre-therapeutic level of reactive oxygen intermediate (ROI) generation by whole capillary blood leukocytes by luminol-dependent chemoluminescence stimulated by barium sulphate crystals and antioxidant activity (AOA) of serum by chemiluminescence activated by rhodamine B in the presence of ferrous iron ions. If ROI is more than 2.7×105 quantum/sec × 4π, AOA is less than 29 relative units, an energotropic therapy is prescribed in the form of oral administration of 30% carnitine 30 mg/kg/day for one month; thereafter ROI and AOA is re-measured. If ROI is less than 2.7×105 quantum/sec × 4π, AOA is more than 29 relative units, the treatment is terminated; if ROI is more than 2.7×105 quantum/sec × 4π, and AOA is less than 29 relative units, continuing the carnitine therapy is indicated in the same dose for another month.

EFFECT: invention enables optimising the drug-induced treatment of secondary mitochondrial dysfunction in the children with congenital urogenital abnormalities by the individual approach, and grounds prescribing the energotropic therapy and its length.

3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new 3-benzofuranylindol-2-one derivatives substituted in position 3 of formula wherein: R1 means a hydrogen atom; R2, R3, R4 equal or different, found in any accessible position of the phenyl ring, means independently a hydrogen atom or a halogen atom; R5 means (C1-6) alkyl group; n means 1; in the form of the base or acid-additive salt, as well as to a therapeutic agent and a pharmaceutical composition based on the above compounds possessing the ghrelin receptor antagonist activity, and to using this compounds for preparing the therapeutic agent for preventing or treating obesity, diabetes, appetite disorders and overweight.

EFFECT: preparing the therapeutic agent used for preventing or treating obesity, diabetes, appetite disorders and overweight.

8 cl, 1 ex

FIELD: medicine.

SUBSTANCE: combined phyto- and physiotherapy is conducted. The phytotherapy involves administering Prolit Super 2 capsules two times a day (at 8 and 14 o'clock) for one month; the physiotherapy provides rectal electrical stimulation by means of AndroGyn for 8 minutes a day, 15 procedures in the therapeutic course.

EFFECT: invention enables improving the sexual function and prostatic microcirculation, and can be used in ambulance situation.

1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to a method of treating a mammal with endometriosis. The claimed method includes the pulse or interrupted peroral introduction of an N-acetyl-L-cysteine-containing pharmaceutical composition for 3-5 successive days with the following 2-4-day break or for 1-3 successive days with the following 1-2-day break, for at least a two-month time period. N-acetyl-L-cysteine in the said method is introduced in a dose, constituting from 20 to 90 mg/kg/day.

EFFECT: claimed method provides the more significant effect with respect to endometriosis symptoms in comparison with the traditional daily introduction of N-acetyl-L-cycteine.

11 cl, 7 dwg, 2 tbl, 3 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises intramuscular administration in the body of the medicinal drug of antioxidant action prior to anticipated calving twice. The first administration is performed 50÷60 days before. The second administration is carried out 15÷20 days prior to anticipated calving. The medicinal drug is used as immunofan which is administered in a dose of 4÷5 ml per animal.

EFFECT: invention is highly effective for prevention of postpartum inflammatory diseases of uterus and mammary gland.

3 tbl, 1 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises intramuscular administration of the tylosin-containing preparation at a dose of 0.05 ml/kg body weight once a day for 3-4 days in all forms of mastitis. The tylosin-containing preparation is used as the preparation of the following composition, wt %: colistin sulphate - 4.0-6.0; tylosin base - 4.0-6.0; benzyl alcohol - 4.0; water for injection - 15.0; 1,2-propylene glycol - 100.0%.

EFFECT: use of the claimed invention enables to improve the therapeutic efficacy of treatment of mastitis.

3 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and concerns a stable composition of nanostructured Sildenafil inhibiting cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDEV) containing a nanostructured Sildenafil base or its pharmaceutically acceptable salts having an average particle size of less than approximately 500nm, a stabilising agent, wherein the composition is prepared in a microfluidics-based continuous-flow tank reactor, and the composition possesses a semi-amorphous structure. The group of inventions also concerns a method for preparing the composition of nanostructured Sildenafil; using the above composition for preparing the pharmaceutical composition for treating male or female sexual dysfunction and pulmonary arterial hypertension.

EFFECT: group of inventions provides the improved solubility of the composition.

8 cl, 11 ex, 14 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of structural formula (I), which can be used for treating diseases mediated by an androgen receptor. In formula (I), R1 means (C2-6)alkyl, (C1-6)alkyloxy, -S(O)m-(C1-6)alkyl, (C1-6)fluoroalkyl, CN or halogen, R2 and R3 are identical or different and mean a hydrogen atom or (C1-9)alkyl, R4, R5, R6, R7 are identical or different and mean a hydrogen or halogen, X means CH or N, Y means either a nitrogen atom, or a carbon atom substituted by (C1-6)alkyl, (C1-6)alkyloxy, (C1-6)fluoroalkyl, a hydrogen atom or halogen; m is equal to 0, 1 or 2.

EFFECT: invention refers to using the compounds for preparing a therapeutic agent for preventing and/or treating hirsutism, androgenetic alopecia, hypertrichosis, atopic dermatitis, disordered sebaceous gland, such as hyperseborrhea, acne, greasy skin or seborrheic dermatitis.

8 cl, 2 tbl, 26 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises intravaginal administration of probiotic preparation "Giprolam" (Lactobacillus fermentum 44/1 and Lactococcus lactis subsp. Lactis 574). "Giprolam" is administered for 5-7 days prior to calving daily at a dose of 100 cm3.

EFFECT: use of the claimed invention promotes to maintain the amount of lactobacilli and bifidobacteria at the physiological level, prevents the colonisation of the genital tract with potentially pathogenic microflora and prevents the occurrence of postpartum infections.

6 tbl, 2 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises the combined use of the tissue preparation on the 1, 3 and 5 days of treatment, and 15% solution of ASD-2f on tetrahydrovit at a dose of 10 ml intramuscularly on the 2, 4 and 6 days of treatment. The tissue preparation is used as biogenic stimulator aminoseleton which is administered subcutaneously into the upper third of the neck in increasing dose of 40-45-50 ml.

EFFECT: method is highly effective for treatment of subclinical mastitis in lactating cows.

3 tbl, 1 ex

FIELD: veterinary medicine.

SUBSTANCE: chemotherapeutic agent is used as N,N-dimethylamino-propylamides of fatty acids of the formula 1 which are used in the form of salts with pharmacologically acceptable acids.

EFFECT: use of the claimed invention is highly effective for treatment of animals with postpartum endometritis.

4 tbl, 2 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises the use of chemotherapeutic agents. The chemotherapeutic agent is used as N,N-dimethylamino-propylamides of fatty acids of the formula 1 which are used in the form of salts with pharmacologically acceptable acids.

EFFECT: use of the claimed invention is highly effective for treatment of endometritis in animals.

4 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: minor amputation of the foot with the further necrectomy is performed. After the application of an antimicrobial bandage and drainage, the wound is hermetised from the environment by the creation of a negative pressure above the wound in a combination with drug treatment. The reatment is performed in two steps. At the first step the wound with the antimicrobial bandage and drainage is first hermetised from above with an adhesive film, with the creation and support of the negative pressure not lower than 80 mm Hg. Urokinase 500000 U is additionally introduced daily intravenously by drop infusion per 100 ml of physiological solution, Vessel-Due-F in a dose of 600 LU per 100 ml of physiological solution and VAP 20 - alprostadil in a dose of 40 mcg per 100 ml of physiological solution. In addition Antistax in capsules is introduced to the patient. At the second stage active 24-hour vacuum aspiration with the change of the negative pressure from 10 to 80 mm Hg within a day is carried out. Additionally introduced is Vessel-Due-F in a dose of 1 capsule with 250 LU 2 times per day between meals and Antistax. At the first and second stages Antistax is introduced in a dose of 2 capsules in the morning 30-40 minutes before meal, daily. Duration of each stage constitutes not less than 7 days.

EFFECT: increase of the treatment efficiency due to the complete and timely purification of the wound from pathological exudates, elimination of the progression of the purulent-necrotic process, increase of the regenerative activity of tissues, activation of local immunity, recovery of microcirculation and oxygenation of the affected tissues.

2 cl, 2 ex

Up!